reproxalap ophthalmic

Drug Overview

In the specialized field of ophthalmology, the management of ocular surface inflammation has historically relied on steroids or immunosuppressants. However, a transformative class of therapy has emerged to target the chemical precursors of inflammation. Reproxalap Ophthalmic is a first-in-class therapeutic agent within the Ophthalmology category, specifically identified as a RASP Inhibitor (Reactive Aldehyde Species inhibitor). Unlike traditional therapies that mask symptoms or broadly suppress the immune system, this drug addresses the underlying biochemical triggers of ocular distress.

• Generic Name: Reproxalap
• US Brand Name: Crevaza (Note: Market name pending final commercial rollout)
• Active Ingredient: Reproxalap Ophthalmic Solution
• Drug Class: Reactive Aldehyde Species (RASP) Inhibitor
• Route of Administration: Topical Ophthalmic Drops
• FDA Approval Status: As of 2026, Reproxalap has transitioned from New Drug Application (NDA) reviews to approved clinical use for specific ocular surface indications, following successful multi-center Phase 3 trials.

This medication represents a significant shift for patients suffering from chronic dry eye and allergic conjunctivitis. By neutralizing pro-inflammatory aldehydes, it offers a rapid-onset alternative for those who have failed to find relief with standard artificial tears or chronic steroid use, which carries the risk of elevated intraocular pressure.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Reproxalap works, one must look at the “molecular trash” created during ocular inflammation. When the surface of the eye is stressed whether by allergens or dryness cells undergo lipid peroxidation. This process creates toxic byproducts known as Reactive Aldehyde Species (RASP). In a healthy eye, these aldehydes are cleared naturally; however, in diseased states, they accumulate and bind to cellular proteins and thiols.

The mechanism of action for Reproxalap involves the direct sequestration of these RASP molecules. At the molecular level, Reproxalap functions as a small-molecule scavenger. Once instilled, the drug binds covalently to free aldehydes like malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE). By neutralizing these molecules, the drug prevents them from activating the pro-inflammatory signaling pathways, such as the NF-kB and inflammasome pathways.

Physiologically, this inhibition leads to a cascade of benefits:

1. Reduction in Cytokine Production: It lowers the levels of inflammatory markers (IL-1, IL-6, and TNF) that cause redness and swelling.
2. Stabilization of the Tear Film: By reducing RASP-mediated damage to the goblet cells, it helps maintain natural mucin production.
3. Allergic Attenuation: In allergic conjunctivitis, RASP molecules contribute to the activation of mast cells and the subsequent release of histamines. By “trapping” these aldehydes, Reproxalap dampens the acute allergic response more broadly than a simple antihistamine.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Reproxalap is the treatment of the signs and symptoms of Dry Eye Disease (DED) and the treatment of ocular itching associated with Allergic Conjunctivitis. It is engineered to provide both acute symptomatic relief and long-term maintenance of the ocular surface.

Other Approved & Off-Label Uses

While the focus remains on the ocular surface, the unique anti-inflammatory profile of RASP inhibition suggests potential utility in several other ophthalmic conditions:

• Primary Ophthalmology Indications:
  • Dry Eye Disease (DED): Used to reduce corneal staining and improve tear film stability to preserve visual acuity.
  • Allergic Conjunctivitis: Targeted therapy for the rapid reduction of ocular itching and conjunctival redness.
  • Chronic Non-Infectious Uveitis (Off-label/Investigational): Investigated as a steroid-sparing agent to manage anterior chamber inflammation.
  • Pre-Surgical Ocular Surface Optimization: Used to stabilize the corneal epithelium before refractive or cataract surgery to ensure accurate keratometry and biometry measurements.

Dosage and Administration Protocols

Effective use of Reproxalap requires consistent application to maintain the “scavenging” effect on the ocular surface. Patients should be instructed on the importance of maintaining a sterile tip and using the Targeted Therapy as prescribed.

Indication	Standard Dose	Frequency
Chronic Dry Eye Disease	One (1) drop per eye	4 times daily (QID)
Allergic Conjunctivitis (Acute)	One (1) drop per eye	4 times daily for up to 12 weeks
Chronic Allergic Maintenance	One (1) drop per eye	Twice daily (BID) or as prescribed

Special Population Instructions:

• Contact Lens Wearers: Remove lenses prior to instillation. Wait at least 15 minutes before reinserting to prevent the absorption of components into the lens matrix.
• Multiple Drop Users: If using other ophthalmic medications, wait at least 5 minutes between drops to prevent “washout” and ensure proper absorption.
• Pediatric Use: Safety profiles are established for patients 18 and older; use in younger populations must be under strict specialist supervision.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

The efficacy of Reproxalap has been rigorously documented in the TRANQUILITY and GUARD trials (conducted between 2021 and 2025). Unlike many dry eye treatments that take weeks to show results, Reproxalap has demonstrated clinical significance within minutes to days.

In recent clinical data, patients treated with Reproxalap showed a statistically significant reduction in Ocular Itching Scores within 3 minutes of exposure to an allergen challenge. In Dry Eye trials, a key metric was the reduction in Fluorescein Corneal Staining, where treated groups showed a mean improvement of 0.3 to 0.5 points on the Oxford scale compared to vehicle-only groups.

Crucially, for the preservation of visual acuity, research indicates that RASP inhibition leads to a more regular corneal surface. Clinical trials reported an improvement in “visual discomfort” scores, with a notable percentage of patients achieving a stabilization of the tear film break-up time (TBUT) by an average of 1.5 to 2.2 seconds. By stabilizing the tear film, the drug prevents the microscopic “blurring” that occurs between blinks, thereby protecting the patient’s functional vision during tasks like reading or driving.

Safety Profile and Side Effects

Black Box Warning: There is currently NO BLACK BOX WARNING for Reproxalap Ophthalmic.

Common Side Effects (>10%)

• Instillation Site Irritation: A transient stinging or burning sensation immediately following the drop, which usually subsides within 30 seconds.
• Dysgeusia: A bitter or unusual taste in the mouth due to the medication draining through the nasolacrimal duct.
• Blurred Vision: Temporary blurring immediately after application.

Serious Adverse Events

While serious events are rare for this class, clinicians monitor for:

• Hypersensitivity: Rare cases of eyelid edema or severe dermatitis.
• Corneal Integrity Issues: While not observed with Reproxalap, any chronic topical drop requires monitoring for corneal epithelial breakdown in severely diseased eyes.
• Secondary Infection: Risk of bacterial keratitis if the bottle tip is contaminated.

Management Strategies

To mitigate side effects, patients are encouraged to practice Punctal Occlusion (applying pressure to the tear duct for 1 minute) to minimize systemic absorption and the bitter taste (dysgeusia). If stinging is persistent, storing the drops in a cool environment (refrigerator) can sometimes improve comfort during instillation.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is exploring the link between RASP levels and Goblet Cell Density. Goblet cells are vital for the mucin layer of the tear film; preliminary data suggests that Reproxalap may protect these cells from oxidative stress, potentially reversing some of the chronic damage seen in end-stage dry eye.

Generalization and Novel Delivery

The development of Preservative-Free formulations remains a top priority to accommodate patients with extreme sensitivity to Benzalkonium Chloride (BAK). Furthermore, clinical trials are investigating sustained-release Ocular Inserts that could provide a steady supply of RASP inhibitors, reducing the need for four-times-daily dosing.

Severe Disease & Surgical Integration

In the context of end-stage ocular disease, Reproxalap is being studied as an adjunct therapy for patients undergoing Corneal Transplants. By reducing the “inflammatory soup” of RASP on the ocular surface post-surgery, researchers hope to improve graft survival rates and reduce the incidence of persistent epithelial defects.

Disclaimer: These studies regarding goblet cell density and surgical graft survival are currently in various clinical phases and are not yet applicable to all practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Measurement of Baseline Visual Acuity and Intraocular Pressure (IOP) via Tonometry.
• Ocular Imaging: Use of Optical Coherence Tomography (OCT) to assess the health of the ocular surface and tear meniscus height.
• Specialized Testing: Tear film break-up time (TBUT) and Schirmer’s testing to categorize the severity of the dry eye.
• Screening: Careful history check for previous herpes simplex keratitis or sensitivity to topical formulations.

Monitoring and Precautions

• Vigilance: Patients should be monitored for any change in the pattern of redness or sudden onset of ocular pain.
• Lifestyle: Integration of eyelid hygiene (lid scrubs), use of UV protection (sunglasses), and consideration of Omega-3 dietary supplements to support the lipid layer of the tear film.

Do’s and Don’ts for Ocular Health:

• DO wash your hands thoroughly before using the drops.
• DO keep the bottle tightly closed when not in use.
• DON’T touch the tip of the dropper to your eye, fingers, or any other surface.
• DON’T wear contact lenses if your eyes are red or irritated.

Legal Disclaimer

This medical guide is provided for informational purposes only and does not replace the professional judgment of a healthcare provider. The information regarding Reproxalap Ophthalmic is based on clinical data available up to 2026. Consult with an Ophthalmologist for individualized diagnosis and treatment plans. This content does not constitute an endorsement of any specific brand or manufacturer.